



DATA CAPTURE SECTION
NATIONAL PHARMACOVIGILANCE CENTER



General notes:

Data Report: National Pharmacovigilance Centre

- **Source:** Spontaneous Vigilance System, National Pharmacovigilance Centre
- **Scope:** Adverse event reports following immunization. These are medical occurrences noted after the administration of a vaccine, but do not necessarily imply a direct causal link to the vaccine.
- **Parameters:**
 1. Routine and COVID-19 vaccine reports (Drug reports excluded)
 2. Data extract from 1 Jan to 31 March 2025.

Understanding Pharmacovigilance:


The National Pharmacovigilance Centre plays a crucial role in post-market vaccine safety monitoring. By collecting and analyzing adverse event reports following immunization, it helps identify serious issues and facilitates interventions to protect public health.

Important Notes:


It is important to understand that reports of adverse events following immunization do not automatically prove that the vaccine caused the event. Careful assessment is necessary to establish any potential relationship.




NUMBER of REPORTS BASED ON ORGANIZATION TYPE




number of reports based on report type




Gender




Report seriousness



number of reports by Serious AEFI




number of reports by outcomes






Top 5 reported Vaccines by Trade name




The top 5 Vaccines by (trade name) reported in Q1 2025.


Top 5 reported AEFIs



The top 5 AEFIs reported in Q1 2025.



AEFIs reports in 2025 vs 2024



Reports count based on regions for year 2025, quarter 1.



Recommendation:

After reviewing the reports and statistics from 2024 and the first quarter of 2025, the recommendation suggests conducting in-person visits or remote meetings in the silent regions of Kingdom of Saudi Arabia to continue achieving the goals outlined in the reporting process. The purpose of these meetings would be to share best practices, address any remaining challenges, and celebrate successes.

Action plan for the quarters in 2025:

- **Improve Reporting Rates for Vaccines:** Focus on enhancing the reporting rate for vaccines throughout 2025.
- **Increase Meeting Frequency:** Ensure that the causality assessment committee meets at least twice every quarter.
- **Establish Criteria for Identifying Silent Reporting Regions:**
 - I. Any area not reaching the target for reporting (at least one report per month).
 - II. Areas with no reports (zero reporting) for three consecutive months.
 - III. Regions with no login activity in the system from regional coordinators or healthcare workers.
- After reviewing the reporting KPIs and statistics for Q1 via the AEFIs dashboard, we identified the regions of Hail and Madinah as silent, along with low reporting in Tabuk, Northern Borders, Al Jouf, Qassim, and Riyadh. We will notify the National Immunization Program (NIP) and schedule meetings with these targeted areas to discuss barriers and potential interventions.
- **Arrange Training Meetings:** Coordinate with the NIP and regional coordinators to schedule appropriate training sessions and perform all necessary activities for the silent regions.
- **Review Barriers:** Identify and assess the problems and challenges that hinder effective reporting through the vigilance system.
- **Follow-Up Reporting:** After conducting physical visits, implement a system for continuous monitoring and follow-up of reporting efforts during the 2nd, 3rd, and 4th quarters of 2025.

- **Conduct Virtual Meetings:** Hold meetings for each region after every quarter to review the extent of improvement in reporting rates.

